© 2017 Pharmstandard Ventures
enGene
Montreal, Canada
Year of Investment: 2015
Strategic Deal with Janssen in October, 2015
Strategic Deal with Takeda in January 2016
enGene
Montreal, Canada
Year of Investment: 2015
Strategic Deal with Janssen in October, 2015
Strategic Deal with Takeda in January 2016
enGene Inc. is a private Canadian biotechnology company developing an innovative mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease (IBD) and diabetes. enGene has developed a proprietary, highly flexible, non-integrating biopolymer-based nucleotide (DNA and siRNA) delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders.

For more information, please visit:
www.engeneinc.com

Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally